Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Abbott and AstraZeneca to co-promote Trilipix (fenofibric acid)

Abbot and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott's Trilipix (fenofibric acid), a medication for use alone or in combination with a statin to treat certain lipid disorders. Under the terms of the agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the United States, excluding Puerto Rico. Specific financial terms were not disclosed.

5 Jun 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Carbon monoxide reverses gastroparesis in mice

Mayo Clinic researchers have shown that very low doses of inhaled carbon monoxide in diabetic mice reverses the condition known as gastroparesis or delayed stomach emptying, a common and painful complication for many diabetic patients. The findings will be presented on June 1 at Digestive Disease Week in Chicago.

1 Jun 2009

One in ten advanced colon cancer patients worry about prescription drug costs

The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a study led by researchers at Dana-Farber Cancer Institute in Boston.

1 Jun 2009

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

Marijuana effectiveness as an HIV self-care strategy

Those in the United States living with HIV/AIDS are more likely to use marijuana than those in Kenya, South Africa or Puerto Rica to alleviate their symptoms, according to a new study published in Clinical Nursing Research, published by SAGE.

31 May 2009

Second death from mosquito-borne disease prompts calls for more spraying programs

The recent death of a second person from Murray Valley Encephalitis (MVE) in Northern Australia has prompted calls for an increase in mosquito control spraying programs.

28 May 2009

FDA grants full approval for Sprycel (dasatinib) for chronic myeloid leukemia

Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Sprycel (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate).

27 May 2009

Extreme caffeinated soft drink diet leaves woman with serious health issues

Reports in the media of a New Zealand woman's extreme Red Bull diet where her weight plummeted from 105kg to 60kg by drinking 10 to 14 cans of the 'energy' drink each day say she has been left with serious health issues.

24 May 2009

FDA approves Samsca (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

22 May 2009

Genentech and Biogen Idec submit applications to FDA for Rituxan in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL).

20 May 2009

A.P. Pharma submits NDA for APF530 in chemo-induced nausea and vomiting

A.P. Pharma, Inc. has announced that it has submitted a New Drug Application (NDA) for its lead product, APF530, to the U.S. Food and Drug Administration (FDA). APF530 is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is a long-acting formulation of granisetron that utilizes the Company's proprietary Biochronomer drug delivery system.

18 May 2009

Ginger reduces post-chemotherapy nausea

People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center.

15 May 2009

The latest news on swine flu

The latest update (# 26) from the World Health Organisation (WHO) reports that as of the 12th of May 2009, 30 countries have officially reported 5,251 cases of influenza A (H1N1) infection.

13 May 2009

Sanofi-aventis to acquire Oforta, oral chronic lymphocytic leukemia treatment

Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

12 May 2009

FDA approves Samsca tablets (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

8 May 2009

Studies indicate why females do not fare as well as men in undergoing angioplasty for heart attacks

Age, condition and treatment delay are among the reasons women who undergo angioplasty for heart attack often do not fare as well as do men, according to two studies presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

Metoclopramide versus droperidol for extreme nausea, vomiting during pregnancy

Nausea and vomiting are telltale indicators of pregnancy, affecting more than 80 percent of future mothers. For a few moms-to-be, symptoms can become so severe that hospitalization is required.

6 May 2009